S2 Medical Gets European Patent for Antimicrobial Wound Tech

S2 Medical, a Linköping-based medical technology company, has been granted a European patent for its innovative antimicrobial peptide technology aimed at wound healing and infection control, according to Medtech Magazine. Approved by the European Patent Office (EPO), the patent specifically covers the technology designated "Plantaricin NC8αβ markedly enhances the effects of antibiotics." Upon approval, the patent will be registered as a Unitary Patent, providing S2 Medical with comprehensive intellectual property protection across a significant portion of the European Union and affiliated countries. This registration simplifies patent management across a substantial economic region. The technology distinguishes itself from existing commercial solutions through a physical mechanism that delivers inherent antimicrobial properties and enhances the efficacy of conventional antibiotics. S2 Medical believes this dual-action functionality positions the technology as a valuable asset for clinicians. The company highlights its potential contribution to combating infections, particularly in the treatment of chronic, non-healing wounds, which remain a significant challenge within the healthcare sector.